Romosozumab and teriparatide for treating osteoporosis

Published on 01 Jun 2023
Last Updated on 04 Jun 2025

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has not recommended:

• Romosozumab or teriparatide reference biologic (Forteo) for inclusion on the MOH List of Subsidised Drugs for treating postmenopausal women with osteoporosis who are at high risk for fracture; and

• Teriparatide reference biologic (Forteo) for inclusion on the MOH List of Subsidised Drugs for treating men with primary or hypogonadal osteoporosis who are at high risk for fracture, or patients with glucocorticoid-induced osteoporosis who are at high risk for fracture

due to uncertain extent of clinical benefit and unfavourable cost-effectiveness compared with subsidised alternatives.

Romosozumab and teriparatide for treating osteoporosis (Updated 4 Jun 2025) [PDF, 152 KB]

PES Anabolic drugs for treating osteoporosis (Updated 4 Jun 2025) [PDF, 117 KB]